Harvest Fund Management Co. Ltd Has $887,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Harvest Fund Management Co. Ltd raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,950 shares of the biopharmaceutical company’s stock after buying an additional 1,145 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Gilead Sciences were worth $887,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Nilsine Partners LLC lifted its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. raised its holdings in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after acquiring an additional 128 shares during the period. Financial Counselors Inc. raised its holdings in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 128 shares during the period. Revolve Wealth Partners LLC raised its holdings in Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC raised its holdings in Gilead Sciences by 10.3% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 140 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Mizuho lowered their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Barclays reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Wells Fargo & Company reduced their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Finally, Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $84.71.

Gilead Sciences Trading Up 0.1 %

NASDAQ:GILD traded up $0.08 during trading hours on Tuesday, hitting $67.03. The stock had a trading volume of 5,239,545 shares, compared to its average volume of 7,302,715. Gilead Sciences, Inc. has a one year low of $65.90 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The company has a market cap of $83.46 billion, a price-to-earnings ratio of 14.90, a P/E/G ratio of 0.92 and a beta of 0.19. The business’s 50 day moving average is $71.68 and its 200-day moving average is $76.46.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the company earned $1.67 EPS. The firm’s revenue was down 3.7% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.55 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.59%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.